A new guideline standardizes best diagnostic practices.
Sponsoring Organizations: U.S. Food and Drug Administration and the American Society of Plastic SurgeonsTarget Audience: Multidisciplinary women's health and cancer treatment teams, including lymphoma oncologists, general and oncologic surgeons, radiation oncologists, pathologists, radiologists, family practice physicians, gynecologists, and plastic surgeons
Background and Objective
Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging T-cell lymphoma that can arise within a malignant effusion or in the scar tissue surrounding textured-surface breast implants. Surgical removal of the implant and resection of the scar capsule and any associated mass is indicated for most cases of early-stage disease. Systemic treat…
Reviewing Author
DisclosuresSpeaker's BureauPhysicians’ Education Resource, LLC
RoyaltiesMcGraw-Hill Professional; UpToDate, Inc.
Editorial BoardsAnnals of Surgical Oncology
Leadership Positions in Professional SocietiesAmerican Society of Breast Surgeons (Chair, Publications Committee)
DisclosuresSpeaker's BureauPhysicians’ Education Resource, LLC
RoyaltiesMcGraw-Hill Professional; UpToDate, Inc.
Editorial BoardsAnnals of Surgical Oncology
Leadership Positions in Professional SocietiesAmerican Society of Breast Surgeons (Chair, Publications Committee)